Frontiers in Immunology (Nov 2022)

Mouse models of lung-specific SARS-CoV-2 infection with moderate pathological traits

  • Sung-Hee Kim,
  • Jiseon Kim,
  • Ji Yun Jang,
  • Ji Yun Jang,
  • Hyuna Noh,
  • Jisun Park,
  • Haengdueng Jeong,
  • Donghun Jeon,
  • Chanyang Uhm,
  • Heeju Oh,
  • Kyungrae Cho,
  • Yoon Jeon,
  • Dain On,
  • Dain On,
  • Suhyeon Yoon,
  • Soo-Yeon Lim,
  • Sol Pin Kim,
  • Youn Woo Lee,
  • Hui Jeong Jang,
  • In Ho Park,
  • In Ho Park,
  • Jooyeon Oh,
  • Jung Seon Seo,
  • Jeong Jin Kim,
  • Sang-Hyuk Seok,
  • Yu Jin Lee,
  • Seung-Min Hong,
  • Se-Hee An,
  • Seo Yeon Kim,
  • Young Been Kim,
  • Ji-Yeon Hwang,
  • Hyo-Jung Lee,
  • Hong Bin Kim,
  • Kang-Seuk Choi,
  • Jun Won Park,
  • Jun-Young Seo,
  • Jun-Won Yun,
  • Jeon-Soo Shin,
  • Jeon-Soo Shin,
  • Jeon-Soo Shin,
  • Ho-Young Lee,
  • Ho-Young Lee,
  • Kyoungmi Kim,
  • Daekee Lee,
  • Ho Lee,
  • Ho Lee,
  • Ki Taek Nam,
  • Je Kyung Seong,
  • Je Kyung Seong,
  • Je Kyung Seong,
  • Je Kyung Seong

DOI
https://doi.org/10.3389/fimmu.2022.1055811
Journal volume & issue
Vol. 13

Abstract

Read online

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) has been a global health concern since 2019. The viral spike protein infects the host by binding to angiotensin-converting enzyme 2 (ACE2) expressed on the cell surface, which is then processed by type II transmembrane serine protease. However, ACE2 does not react to SARS-CoV-2 in inbred wild-type mice, which poses a challenge for preclinical research with animal models, necessitating a human ACE2 (hACE2)-expressing transgenic mouse model. Cytokeratin 18 (K18) promoter-derived hACE2 transgenic mice [B6.Cg-Tg(K18-ACE2)2Prlmn/J] are widely used for research on SARS-CoV-1, MERS-CoV, and SARS-CoV-2. However, SARS-CoV-2 infection is lethal at ≥105 PFU and SARS-CoV-2 target cells are limited to type-1 alveolar pneumocytes in K18-hACE2 mice, making this model incompatible with infections in the human lung. Hence, we developed lung-specific SARS-CoV-2 infection mouse models with surfactant protein B (SFTPB) and secretoglobin family 1a member 1 (Scgb1a1) promoters. After inoculation of 105 PFU of SARS-CoV-2 to the K18-hACE2, SFTPB-hACE2, and SCGB1A1-hACE2 models, the peak viral titer was detected at 2 days post-infection and then gradually decreased. In K18-hACE2 mice, the body temperature decreased by approximately 10°C, body weight decreased by over 20%, and the survival rate was reduced. However, SFTPB-hACE2 and SCGB1A1-hACE2 mice showed minimal clinical signs after infection. The virus targeted type I pneumocytes in K18-hACE2 mice; type II pneumocytes in SFTPB-hACE2 mice; and club, goblet, and ciliated cells in SCGB1A1-hACE2 mice. A time-dependent increase in severe lung lesions was detected in K18-hACE2 mice, whereas mild lesions developed in SFTPB-hACE2 and SCGB1A1-hACE2 mice. Spleen, small intestine, and brain lesions developed in K18-hACE2 mice but not in SFTPB-hACE2 and SCGB1A1-hACE2 mice. These newly developed SFTPB-hACE2 and SCGB1A1-hACE2 mice should prove useful to expand research on hACE2-mediated respiratory viruses.

Keywords